Monoprophylaxis with cephalosporins for transrectal prostate biopsy after the fluoroquinolone-era: a multi-institutional comparison of severe infectious complications

  • Background: To compare severe infectious complication rates after transrectal prostate biopsies between cephalosporins and fluoroquinolones for antibiotic monoprophylaxis. Material and Methods: In the multi-institutional cohort, between November 2014 and July 2020 patients received either cefotaxime (single dose intravenously), cefpodoxime (multiple doses orally) or fluoroquinolones (multiple-doses orally or single dose intravenously) for transrectal prostate biopsy prophylaxis. Data were prospectively acquired and retrospectively analyzed. Severe infectious complications were evaluated within 30 days after biopsy. Logistic regression models predicted biopsy-related infectious complications according to antibiotic prophylaxis, application type and patient- and procedure-related risk factors. Results: Of 793 patients, 132 (16.6%) received a single dose of intravenous cefotaxime and were compared to 119 (15%) who received multiple doses of oral cefpodoxime and 542 (68.3%) who received fluoroquinolones as monoprophylaxis. The overall incidence of severe infectious complications was 1.0% (n=8). No significant differences were observed between the three compared groups (0.8% vs. 0.8% vs. 1.1%, p=0.9). The overall rate of urosepsis was 0.3% and did not significantly differ between the three compared groups as well. Conclusion: Monoprophylaxis with third generation cephalosporins was efficient in preventing severe infectious complications after prostate biopsy. Single intravenous dose of cefotaxime and multiday regimen of oral cefpodoxime showed a low incidence of infectious complications <1%. No differences were observed in comparison to fluoroquinolones.

Download full text files

Export metadata

Metadaten
Author:Mike WenzelORCiDGND, Jost von Hardenberg, Maria-Noemi Welte, Samuel Doryumu, Robert Benedikt HöhGND, Clarissa Wittler, Thomas Höfner, Maximilian Kriegmair, Maurice Stephan Michel, Felix ChunORCiDGND, Jonas Herrmann, Philipp Mandel, Niklas Christian Westhoff
URN:urn:nbn:de:hebis:30:3-614058
DOI:https://doi.org/10.3389/fonc.2021.684144
ISSN:2234-943X
Parent Title (English):Frontiers in oncology
Publisher:Frontiers Media
Place of publication:Lausanne
Document Type:Article
Language:English
Date of Publication (online):2021/06/10
Date of first Publication:2021/06/10
Publishing Institution:Universitätsbibliothek Johann Christian Senckenberg
Release Date:2021/07/05
Volume:11
Issue:art. 684144
Page Number:7
First Page:1
Last Page:7
HeBIS-PPN:484966790
Institutes:Medizin
Dewey Decimal Classification:6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit
Sammlungen:Universitätspublikationen
Open-Access-Publikationsfonds:Medizin
Licence (German):License LogoCreative Commons - Namensnennung 4.0